Open to Enrollment Studies

Hematology & Oncology (Cancer)

BREAST CANCER COLLABORATIVE REGISTRY
An investigator-initiated, multisite institutional, non-interventional trial sponsored by the University of Nebraska Medical Center. The registry is focused on the collection of detailed information about participants to help create a resource that will be helpful to researchers in future studies related to breast cancer. It is the hope that future research using information from this registry will lead to improved diagnosis, prevention, and treatment of breast cancers.
Principal investigator: Melissa Kaptanian, MD
Contact:  Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org
Or Deptresearch@logan.org   -   (406) 752-7636


CHIESI CUSA-081-HEM (READY-1) Trial
A Phase 3, Randomized, Double-Blind, Active and Placebo- Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
Principal Investigator, Elise Anderes, MD
Contact: Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org
Or Deptresearch@logan.org   -   (406) 752-7636


MONTANA CANCER CONSORTIUM (NCORP)TRIALS
The Montana Cancer Consortium is an NCI Community Oncology Research Program (NCORP) that gives patients at Logan Health access to more than 80 clinical trials for various disease sites, including brain, breast, lung, gastrointestinal, genitourinary, gynecological, lymphomas, melanoma, multiple myeloma, and neuroendocrine diseases. These trials are sponsored by cooperative groups in the U.S. (i.e., ALLIANCE, ECOG-ACRIN, NRG, SWOG) and the National Cancer Institute (NCI). This includes treatment trials, cancer prevention trials, and cancer care delivery research (CCDR). For more information on the open trials available, visit www.mtcancer.org
Site Principal Investigator, Elise Anderes, MD
Contact: Mandy Bartlett, RN, CCRC  (406) 607-8021 or abartlett@logan.org
Or Deptresearch@logan.org   -   (406) 752-7636

 

Cardiology

AEGIS II
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel group
Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
Principal investigator: Eve Gillespie, MD, PhD
Contact: Deptreresearch@logan.org   -   (406) 752-7636

CARE-HK in HF Registry HQ-NIS-CHF-07.2020
Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalaemia or at High Risk of Hyperkalaemia
Principal investigator: Eve Gillespie, MD, PhD
Contact: Deptresearch@logan.org   -   (406) 752-7636

FineArts-HF
A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)
Principal Investigator: Eve Gillespie, MD, PhD
Contact: Deptresearch@logan.org   -   (406) 752-7636
 
VICTOR HFrEF – MK1242-035
A Pivatol Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults with Chronic Heart Failure With Reduced Ejection Fraction
Principal Investigator: Eve Gillespie, MD, PhD
Contact: Deptresearch@logan.org   -   (406) 752-7636


 

COVID-19

I-Spy COVID-19
An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients
Principal Investigator: Timothy Obermiller, MD
Contact:  Mandy Bartlett, RN, CCRC @ 406-607-8021 abartlett@logan.org
or Deptresearch@logan.org   -   (406) 752-7636


 

Endocrinology

Contact: DEPTresearch@logan.org   -  (406) 752-7636 for ongoing or upcoming clinical trials.



 

Gastroenterology

Contact: DEPTresearch@logan.org - (406) 752-7636 for ongoing or upcoming clinical trials


 

Rheumatology

INSPIRE 1 – TILD-19-07
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or jwyatt@logan.org
Or DEPTresearch@logan.org   -   (406) 752-7636
 
 
APEX PSA – CNTO1959PSA3004
 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutanuously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants with Active Psoriatic Arthristis. APEX
Site Principal Investigator: Roger Diegel, MD
Contact: Jaime Wyatt, CCRC (406) 755-1460 or jwyatt@logan.org
Or Deptresearch@logan.org   -   (406) 752-7636